| HSCT cohort | NHL cohort | |
|---|---|---|
| Age (median, range) years | 58(19-73) | 57(29-72) |
| Sex (male/female) (n, %) | 10(59)/7(41) | 3(60)/2(40) |
| Diagnosis (n) | AML/ALL(14), MDS/MPN(3) | NHL(4), monoclonal gammopathy(1) |
| Prior CAR T-cell therapy (n, %) | 2(12) | 0 |
| Anti-CD20/22 mAb therapy within 6 months prior to vaccination (n, %) | 3(18) | 5(100) |
| GVHD status at vaccination (n, %) | ||
| - no active GVHD | 5(29) | |
| - late onset acute GVHD (grade 2) | 2(12) | |
| - chronic GVHD (moderate/severe) | 10(1/9), (59) | |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.